<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01790997</url>
  </required_header>
  <id_info>
    <org_study_id>DLBS1033-UST-001.11</org_study_id>
    <nct_id>NCT01790997</nct_id>
  </id_info>
  <brief_title>Efficacy of DLBS1033 in Patients With Acute Ischemic Stroke</brief_title>
  <official_title>The Role of DLBS1033 in Evaluating Bleeding Profile and Clinical Outcome in Patients With Acute Ischemic Stroke: Comparison With Aspirin and Clopidogrel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dexa Medica Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dexa Medica Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 3-arm, prospective, randomized, double-blind, and controlled clinical study, with 3
      months of treatment to evaluate efficacy of DLBS1033 in bleeding profile and clinical outcome
      in patients with acute ischemic stroke compared with aspirin and clopidogrel, as active
      controls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There will be 3 groups of treatment; each group will consist of 43 subjects with the
      treatment regimens :

        -  Treatment I : 1 tablet of DLBS1033 490 mg thrice daily, after meal

        -  Treatment II : 1 tablet of aspirin 80 mg once daily, after meal

        -  Treatment III : 1 tablet of clopidogrel 75 mg once daily, after meal

      Bleeding profile (by measuring INR value, PT, and aPTT) and clinical outcome (by measuring
      Gadjah Mada Stroke Scale and Barthel Index) to evaluate the efficacy of the investigational
      drug will be performed at baseline and end of study (Month 3rd). General condition of the
      subjects will be followed-up every month over three months of study medication.

      Physiotherapy will be provided to the subjects by the assigned Physiotherapist.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in INR value</measure>
    <time_frame>3 Months</time_frame>
    <description>Change in INR (international normalized ratio) value from baseline to end of study (Month 3rd)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in PT</measure>
    <time_frame>3 Months</time_frame>
    <description>Change in PT (prothrombin time) from baseline to end of study (Month 3rd)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in aPTT</measure>
    <time_frame>3 Months</time_frame>
    <description>Change in aPTT (activated-partial thromboplastin time) from baseline to end of study (Month 3rd)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gadjah Mada Stroke Scale</measure>
    <time_frame>3 Months</time_frame>
    <description>Change in Gadjah Mada Stroke Scale from baseline to end of study (Month 3rd)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Barthel Index</measure>
    <time_frame>3 Months</time_frame>
    <description>Change in Barthel Index from baseline to end of study (Month 3rd)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Treatment I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet of DLBS1033 490 mg thrice daily, after meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 tablet of aspirin 80 mg once daily, after meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment III</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 tablet of clopidogrel 75 mg once daily, after meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DLBS1033</intervention_name>
    <description>1 tablet of DLBS1033 490 mg thrice daily, after meal</description>
    <arm_group_label>Treatment I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>1 tablet of aspirin 80 mg once daily, after meal</description>
    <arm_group_label>Treatment II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>1 tablet of clopidogrel 75 mg once daily, after meal</description>
    <arm_group_label>Treatment III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects aged 20-80 years old

          -  Having non-bleeding stroke in CT scan examination

          -  Having stroke attack onset â‰¤ 96 hours

          -  Living in 100 km from RSUP Dr Sardjito Jogjakarta

        Exclusion Criteria:

          -  Having recurrence stroke

          -  Having Transient Ischemic Attack (TIA)

          -  Have been regularly taking anti-aggregation agent

          -  Having intracerebral and subarachnoid bleeding stroke

          -  Subjects and their family do not know when the stroke symptoms appeared

          -  History of haemostasis disorder

          -  History of or will have surgery within 6 months prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ismail Setyopranoto, dr., SpS(K)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stroke Unit, Department of Neurology, Faculty of Medicine, Gadjah Mada University, dr. Sardjito Hospital, Jogjakarta, Indonesia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stroke Unit, Department of Neurology, Faculty of Medicine, Gadjah Mada University, dr. Sardjito Hospital</name>
      <address>
        <city>Yogyakarta</city>
        <state>Jogjakarta</state>
        <zip>55281</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2013</study_first_submitted>
  <study_first_submitted_qc>February 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2013</study_first_posted>
  <last_update_submitted>June 3, 2014</last_update_submitted>
  <last_update_submitted_qc>June 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DLBS1033</keyword>
  <keyword>Lumbrokinase</keyword>
  <keyword>Acute ischemic stroke</keyword>
  <keyword>Bleeding profile</keyword>
  <keyword>Clinical outcome</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Clopidogrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

